(Q83171376)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

0 references

1 reference

title

The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

stem cell transplantation

19 January 2020

main subject

1 reference

M Mohty

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

R F Duarte

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

S Croockewit

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

K Hübel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

G Kvalheim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

N Russell

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

1-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21224858%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2010.224

19 January 2020

exact match

0 references

cites work

Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Improving stem cell mobilization strategies: future directions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Kinetics of peripheral blood stem cell mobilization following G-CSF-supported chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Hematopoietic stem cell trafficking: regulated adhesion and attraction to bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Clinical pharmacokinetics of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.224

7 January 2021